Consequently, the European Association for the Study of the Liver (EASL) clinical practice guidelines described that the utility of AFP as biomarker is suboptimal in terms of cost-effectiveness for routine surveillance of early HCC (evidence low) [42]. The gene discussed is AFP; the disease is hepatocellular carcinoma.